Sinovac Hopes to Begin Mumps Vaccine Trial
ChinaBio Today submits:
Sinovac Biotech Ltd. (NSDQ: SVA) said its subsidiary Sinovac Dalian, a JV formed in January 2010, has applied to the SFDA to begin clinical trials of a mumps vaccine. The application is the first from the JV and also the first live attenuated vaccine from Sinovac. Sinovac has vaccines for measles and rubella in the works, which it plans to combine into a measles, mumps, rubella (MMR) vaccine for government purchasing.
In January, Sinovac paid 60 million RMB ($8.8 million) for a 30% stake in the Sinovac Dalian JV. At the same time, Sinovac agreed to add another 50 million RMB ($7.5 million) in capital before the end of 2010, giving it a majority 55% ownership.